Cantor Fitzgerald Sticks to Their Hold Rating for Universal Health (UHS)
Cantor Fitzgerald analyst Sarah James reiterated a Hold rating on Universal Health yesterday and set a price target of $229.00. The company’s shares closed yesterday at $204.33.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
James covers the Healthcare sector, focusing on stocks such as CVS Health, Acadia Healthcare, and Molina Healthcare. According to TipRanks, James has an average return of 4.7% and a 54.40% success rate on recommended stocks.
In addition to Cantor Fitzgerald, Universal Health also received a Hold from RBC Capital’s Ben Hendrix in a report issued on February 17. However, today, TipRanks – Google reiterated a Buy rating on Universal Health (NYSE: UHS).
Based on Universal Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.49 billion and a net profit of $445.94 million. In comparison, last year the company earned a revenue of $4.11 billion and had a net profit of $332.4 million
Read More on UHS:
Disclaimer & DisclosureReport an Issue
- Universal Health price target raised to $320 from $302 at UBS
- Universal Health Granted New Trial in Nevada Verdict
- Universal Health price target raised to $215 from $190 at BofA
- Sell Rating on Universal Health: Weaker Underlying Demand, Policy Risks, and Overvalued Shares Support Underperform Stance
- Universal Health price target raised to $268 from $262 at Barclays
